Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Premium Biopharma Funds Deliver Rare Monthly Gains Stephen Taub The Office Managing Sam Zell’s Wealth Scales Up Direct Deals With Family Capital and PE Precision John Crabb Why Are Silver and Platinum Outperforming as Portfolio Diversifiers to Gold? Sponsored by CME Group